The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an ...

Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has announced an update on its ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most undervalued stocks. Biogen Inc. (NASDAQ:BIIB) is a global biotechnology leader ...

May 11—(StatePoint) IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ages of 20 and 40, with an annual global incidence of 2.5 cases ...

HI-Bio is focused on developing felzartamab in a number of autoantibody-driven immune-mediated diseases, including primary membranous nephropathy (PMN), IgA nephropathy (IgAN), antibody-mediated ...

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024. Oct. 26, 2024 8:15 PM ET Biogen Inc. (BIIB) ...

--Biogen Inc.– today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in people living with IgA nephropathy. The ...

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an ...